Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP607977.RAjIwo_fT32zpJm597QTHLRFkSozYgNChYO2g30DIlpKU130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP607977.RAjIwo_fT32zpJm597QTHLRFkSozYgNChYO2g30DIlpKU130_provenance.
• NP612717.RAmb-wzBEK9q8jf9wXrEv9EFtxwjThrfWq-MNnKGQJozA130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP612717.RAmb-wzBEK9q8jf9wXrEv9EFtxwjThrfWq-MNnKGQJozA130_provenance.
• assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP341609.RAYhbGvzXAHFkf-PinHYzh1mC1aDVEi4wJPgh9-7fIuKs130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341609.RAYhbGvzXAHFkf-PinHYzh1mC1aDVEi4wJPgh9-7fIuKs130_provenance.
• NP12171.RA7_3NGOBdW8G4G7Grq5sKJ9wpdVdXwqXjlh6mdm79V30130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP12171.RA7_3NGOBdW8G4G7Grq5sKJ9wpdVdXwqXjlh6mdm79V30130_provenance.
• NP12163.RAstihrvXnvXEz2xYxTl75toGz5uzWYTLRz_MI8hH5l6w130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP12163.RAstihrvXnvXEz2xYxTl75toGz5uzWYTLRz_MI8hH5l6w130_provenance.
• NP341067.RADEZ_iDrzNLvrtxUYVRO3qaDavXJwzOzgPHJUd2ah2eE130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341067.RADEZ_iDrzNLvrtxUYVRO3qaDavXJwzOzgPHJUd2ah2eE130_provenance.
• NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451650.RAegWLMOpdFMxm-CL-8h86Zlqo2POvE2aP6Rdh2tY513E130_provenance.
• NP451653.RAbtkJ3NU_ZxXUWZLImW6gUDDmzwSPKtxGlYxl3hI02DQ130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451653.RAbtkJ3NU_ZxXUWZLImW6gUDDmzwSPKtxGlYxl3hI02DQ130_provenance.
• NP451657.RAWYgxQQCG_IGYfXLgAS5-khBZjGBimIy5M0naBufa5ZU130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451657.RAWYgxQQCG_IGYfXLgAS5-khBZjGBimIy5M0naBufa5ZU130_provenance.
• NP341565.RAoyjust_AB6otJKuWZj7uPAxXn4ngRdLMK0LGP2P3fvs130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341565.RAoyjust_AB6otJKuWZj7uPAxXn4ngRdLMK0LGP2P3fvs130_provenance.
• NP340966.RAM_raPjzngnLD2btrJuGETfoGduCpDBy6prZFlm23wOg130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP340966.RAM_raPjzngnLD2btrJuGETfoGduCpDBy6prZFlm23wOg130_provenance.
• NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_assertion description "[In a survival analysis, patients homozygous for CYP2B6*5 (n = 3) or CYP2C19*2 (n = 4) had a higher probability of reaching ESRD (P = 0.0005) and of doubling the creatinine level (P = 0.0005) as well as a trend toward a lower probability of achieving a complete renal response (P = 0.051).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP451654.RAJ9fH3RQf9oKkhEJYJdONF76rn0copCTpZj3D8qmAy6Q130_provenance.